Navigation Links
AbbVie and Alvine to Collaborate on Investigational Oral Therapy for Celiac Disease
Date:5/14/2013

al need," said Abhay Joshi , Ph.D., president and chief executive officer, Alvine.  "We are pleased to have an industry leader in gastroenterology as a collaborator, whose considerable global development reach can be focused on getting this novel therapy to more patients."

Under the terms of the agreement, AbbVie will make an initial upfront payment of $70 million for an exclusive option to either acquire the assets relating to ALV003, or the equity of the company. Alvine will maintain responsibility for Phase 2 clinical development, and upon successful completion of the approximately 500 patient Phase 2b study, AbbVie may exercise its option for the agreed upon additional consideration.  Alvine will also be entitled to receive a milestone payment upon AbbVie's initiation of Phase 3 development.  In collaboration with AbbVie Biotech Ventures, Inc., a subsidiary of AbbVie dedicated to making early investments in emerging biotech and pharmaceutical companies, AbbVie was an early investor in Alvine Pharmaceuticals.

About Celiac Disease

Celiac disease is the most common autoimmune disease, affecting approximately 6 million people in the U.S. and E.U.  Celiac disease is an acquired autoimmune disorder that develops in genetically susceptible individuals after exposure to dietary gluten, the protein found in wheat, rye and barley that humans cannot fully digest.  Celiac disease is a systemic illness that can affect many organ systems, causing chronic gastrointestinal symptoms, such as nausea, diarrhea, and constipation, and can potentially cause serious medical consequences, including malabsorption, osteoporosis, anemia, infections and malignancies.  Currently there is no approved therapy for celiac disease and the only option for patients is to attempt to follow a strict, life-long gluten-free diet.

About Alvine Pharmaceuticals 

Alvine Pharmaceuticals, Inc. is a private,
'/>"/>

SOURCE AbbVie
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AbbVie to Present at Bank of America Merrill Lynch 2013 Health Care Conference
2. AbbVies Investigational HCV Regimen Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration
3. AbbVie CF Scholarship Application Now Available for Exceptional Undergraduate and Graduate Students with Cystic Fibrosis
4. AbbVie Reports First-Quarter 2013 Financial Results
5. AbbVie to Host First-Quarter Earnings Conference Call
6. Receptos Licenses Anti-Interleukin-13 Antibody from AbbVie for Phase 2 Development in Orphan Disease
7. AbbVie to Present at Barclays Global Health Care Conference
8. AbbVie Issues Inaugural Full-Year Outlook for 2013
9. AbbVie Named to S&P 500 Dividend Aristocrat Index
10. Domain Associates and Elite Consulting Collaborate to Create and Invest in Life Science Companies in China
11. InternetArray Collaborates with Health Sciences Group to Fund Medical Marijuana Social Media/Mobile Apps Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... An analysis done by the CVS Health ... a new and expensive treatment for Hepatitis C introduced ... several months (May through August 2014) there has been ... This suggests another surge of patients will begin therapy ... efficacy and shorter duration are introduced in the Fall. ...
(Date:9/17/2014)... Utah , Sept. 17, 2014  NuView ... exclusive global licensing and collaboration agreement with Otsuka ... commercialize NuView,s investigative genomic-based diagnostic biomarker to detect ... also includes all other future diagnostic-imaging applications. NuView ... in-vivo therapeutic delivery and in-vitro urine screen applications. ...
(Date:9/17/2014)... LAWRENCEVILLE, N.J. , Sept. 17, 2014 /PRNewswire-USNewswire/ ... that details how to implement GS1 Standards to ... (DSCSA), and enhance patient safety and security in ... Applying GS1 Standards to U.S. Pharmaceutical Supply ... Chain Security Act , was developed in ...
Breaking Medicine Technology:CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 2CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 3CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 3NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 5New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 2New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 3New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 4
... - Opexa,Therapeutics, Inc. (NASDAQ:OPXA), a company involved ... today,announced positive top-line data in an open-label ... T-cell vaccine,Tovaxin(TM), for multiple sclerosis (MS). In ... remitting (RRMS),and secondary progressive (SPMS) subjects, Tovaxin ...
... 2007 - “In anaplastic,astrocytoma, AP 12009 as a ... Wong, M.D., Stanford,University, California, U.S.A. commented on the ... 12009, under development,by Antisense Pharma. Prof. Wong discussed ... session on central nervous system tumors,at the 43rd ...
Cached Medicine Technology:Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Extension Trial with Tovaxin for Multiple Sclerosis 2Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Extension Trial with Tovaxin for Multiple Sclerosis 3Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Extension Trial with Tovaxin for Multiple Sclerosis 4Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Extension Trial with Tovaxin for Multiple Sclerosis 5Antisense Pharma: Promising Phase IIb Results of Targeted Therapy,with AP 12009 in Recurrent Anaplastic Astrocytoma 2Antisense Pharma: Promising Phase IIb Results of Targeted Therapy,with AP 12009 in Recurrent Anaplastic Astrocytoma 3Antisense Pharma: Promising Phase IIb Results of Targeted Therapy,with AP 12009 in Recurrent Anaplastic Astrocytoma 4
(Date:9/17/2014)... gene manipulation these sound like the ideas ... they are components of an exciting new approach ... animal models of metastatic prostate cancer, scientists at ... of Molecular Medicine and Johns Hopkins Medical Institutions ... approach that could revolutionize doctors, ability to see ...
(Date:9/17/2014)... Tidewater Physical Therapy and ... for football players and their parents at its Newport ... open at 6:30 p.m. for athletes and parents to ... and physical therapists. The workshop will start at 7 ... News Tidewater Performance Center, which features sports performance and ...
(Date:9/17/2014)... adjourns this month for the November elections, one of ... way out the chamber door will be the Sustainable ... Act of 2014. In a new commentary in the ... what he and other advocates saw as the merits ... how Medicare pays doctors will return for the next ...
(Date:9/17/2014)... The Food and Drug Administration (FDA) ... to consider: , 1. The appropriate ... 2. The potential for adverse cardiovascular outcomes ... litigation ongoing, an informally-organized litigation group subcommittee prepared a ... replacement therapy. Among others, ZKB attorney Michelle L. Kranz ...
(Date:9/17/2014)... Leading eco-friendly beauty brand , ... its new vegan and gluten-free Sugar Cane Fruit Mask. ... the results skincare testers were looking for. , ... active mask that provided results, and I think I ... Cane Fruit Mask combines Willow bark (Salix Alba extract), ...
Breaking Medicine News(10 mins):Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 3Health News:Tidewater Physical Therapy and Performance Services and recruit757 To Host Football Scholarship Seminar 2Health News:Tidewater Physical Therapy and Performance Services and recruit757 To Host Football Scholarship Seminar 3Health News:Failed Medicare payments law remains relevant 2Health News:Failed Medicare payments law remains relevant 3Health News:FDA Advisory Committee Holds Hearing on Testosterone Safety 2Health News:EcoBeauty Brand Lotus Moon Unveils New Gluten-Free Sugar Cane Fruit Mask 2
... , March 11 As reported in today,s ... Americans with atrial fibrillation are now on notice that the over-zealous ... are not approved by the U.S. Food and Drug Administration (FDA) ... doctors, and hospitals, decisions about treatment for their patients, heart conditions. ...
... snorting cocaine among 12-year-olds, study finds , THURSDAY, March ... inhalants to get high than marijuana, cocaine and hallucinogens ... deadly inhalants include aerosol computer cleaners, glue, hair sprays, ... can cause addiction or sudden death from cardiac arrest. ...
... sign, but exercise regimens can help, experts say , THURSDAY, ... researchers report that preseason measurements of rotator cuff strength can ... developing a shoulder injury during play. , "We found certain ... players are more likely to incur injury that requires surgery," ...
... key to more effective treatment for Alzheimer,s disease and other ... test developed at the University of Tennessee is more than ... diseases. The test, called CST -- for computerized self ... simple for medical professionals to administer and for patients to ...
... monkey babies born to mothers who had the flu while ... to those observed in human patients with schizophrenia, a study ... of North Carolina at Chapel Hill has found. The ... is the first study done with monkeys that examines the ...
... Mo. While there are many benefits of losing weight, ... During weight loss, bones are being remodeled - breaking down ... rate. As a result, bone density is reduced, causing increased ... that weight-bearing exercise, in this case, fast walking or jogging, ...
Cached Medicine News:Health News:Whistleblower Alerts Americans to Dangers of Risky Unapproved Treatment for Atrial Fibrillation 2Health News:Whistleblower Alerts Americans to Dangers of Risky Unapproved Treatment for Atrial Fibrillation 3Health News:Whistleblower Alerts Americans to Dangers of Risky Unapproved Treatment for Atrial Fibrillation 4Health News:Whistleblower Alerts Americans to Dangers of Risky Unapproved Treatment for Atrial Fibrillation 5Health News:Whistleblower Alerts Americans to Dangers of Risky Unapproved Treatment for Atrial Fibrillation 6Health News:Inhalant Abuse a Deadly Middle-School Concern 2Health News:Pre-Season Test Spots Baseball Pitchers at Risk of Injury 2Health News:Pre-Season Test Spots Baseball Pitchers at Risk of Injury 3Health News:New Alzheimer's test offers better opportunities for early detection 2Health News:Mother's flu during pregnancy may increase baby's risk of schizophrenia 2Health News:Weight-bearing exercise does not prevent increased bone turnover during weight loss 2
... 200 series offers a range of ... The design delivers therapy to meet ... promote results in commercial and clinical ... differentiator in the SleepStyle 200 series ...
... The SleepStyle 200 series offers a ... CPAP models. The design delivers therapy ... Performance features promote results in commercial ... The strongest differentiator in the SleepStyle ...
The SleepStyle 600 series with ThermoSmart delivers humidification with anti-rainout benefits. ThermoSmart technology offers a heated breathing tube that allows the constant delivery of optimal level...
The S7 Lightweight offers the comfort and reliability of the award-winning S7 series in a convenient, affordable device....
Medicine Products: